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ScienceDirectImmunoglobulin E (IgE) is pathogenic in allergic diseases
such as asthma, allergic rhinitis, atopic dermatitis, and food
allergy. Recent studies using genetically modified IgE
reporter mice indicate that the majority of serum IgE in mice
is produced by short-lived IgE plasma cells, with minor
contributions from long-lived IgE plasma cells, and implicate
IgG1 and IgE memory B cells as potential sources of IgE
memory. Clinical studies using antibodies against IL-13 or
the IL-4 and IL-13 receptor subunit IL-4Ra, as well as an
antibody against the M1 prime domain of human membrane
IgE, indicate that, similar to mice, a proportion of IgE in
humans is derived from ongoing IgE immune responses
and short-lived plasma cells. Targeting IgE production
may lead to new therapies for the treatment of allergic
diseases.
Addresses
1Department of Immunology, Genentech Inc., 1 DNA Way, South San
Francisco, CA 94080, USA
2Department of Pharmacodynamic Biomarkers, Genentech Inc., 1 DNA
Way, South San Francisco, CA 94080, USA
Corresponding authors: Wu, Lawren C (lawren@gene.com)
Scheerens, Heleen (scheerens.heleen@gene.com)
Current Opinion in Cell Biology 2014, 31:8–15
This review comes from a themed issue on Allergy and
hypersensitivity
Edited by Anne Sperling and Mark Ansel
For a complete overview see the Issue and the Editorial
Available online 25th August 2014
http://dx.doi.org/10.1016/j.coi.2014.08.001
0952-7915/# 2014 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/)
Introduction
Immunoglobulin E (IgE) mediates anaphylaxis reactions
that are pathogenic in allergic diseases such as asthma,
allergic rhinitis, atopic dermatitis, and food allergy [1]. In
patients with these diseases, total and allergen-specific IgE
levels are elevated compared to healthy individuals. Treat-
ment of moderate-to-severe asthmatics who are poorly
controlled on inhaled corticosteroid therapy with a neu-
tralizing anti-IgE monoclonal antibody (omalizumab)
decreases free serum IgE levels and reduces asthma
exacerbations [2]. Omalizumab does not significantly
affect IgE production in these patients, at least in the first
year of treatment [3]. Therefore, therapies that inhibit IgE
production may yield new treatments for allergic diseases.
In this review, we summarize our understanding of IgECurrent Opinion in Immunology 2014, 31:8–15 production in vivo, focusing on recent studies in mice that
examine the biology of IgE-producing plasma cells and the
sources of IgE memory. We discuss approaches for inhibit-
ing IgE production either by neutralizing the cytokines IL-
4 and IL-13 or by targeting IgE-switched B cells directly
through the membrane IgE B cell receptor (BCR). Finally,
we summarize the effects of therapeutics targeting IL-4,
IL-13, IL-4Ra, or the membrane IgE BCR on IgE pro-
duction in human clinical studies.
IgE production and memory in mice
IgE exists in two forms, a membrane BCR form that is
expressed on IgE-switched B cells and a secreted form
that is produced by IgE plasma cells (Figure 1a). Class
switch recombination of naı¨ve B cells to IgE-switched
cells requires the cytokines IL-4 in mice and either IL-4
or IL-13 in humans [4,5]. Both primary and memory IgE
antibody responses are generated through a pathway that
requires membrane IgE-expressing cells, since these
responses are absent in mice in which membrane IgE
expression is abolished without affecting secreted IgE [6].
Consistent with this, mice in which the transmembrane
and/or cytoplasmic domains of membrane IgE are modi-
fied have altered primary and memory IgE responses
[6,7].
The pathway of B cell differentiation to IgE production,
including the location and lifespan of IgE-producing
plasma cells and the identity of the memory B cells that
give rise to IgE memory responses, has been poorly
understood due to difficulties in identifying IgE-switched
B cells in vivo [8,9,10,11]. Recently, three separate
groups have generated IgE reporter mice in which a
fluorescent protein is associated with either transcription
(M1 prime GFP knockin mice [12,13,14,15,16] and
CeGFP mice [17]) or translation (Verigem mice
[18]) of the membrane IgE BCR (Figure 1b). Studies
utilizing these reporter mice, as well as earlier studies that
utilized mice with monoclonal T and B cells [19], have
greatly increased the understanding of IgE production
and memory and have revealed several mechanisms that
limit IgE responses in vivo [10,11].
IgE antibody responses in mice are typically transient and
are not sustained like IgG1 antibody responses [20,21].
Studies of Verigem mice revealed that early IgE
responses are generated from short-lived IgE plasma cells
located in extrafollicular foci. Late IgE responses arise
from germinal centers, but in contrast to IgG1 germinal
center B cells, which are sustained over time and which
give rise to long-lived IgG1 plasma cells, IgE germinal
center B cells do not persist and are predisposed towww.sciencedirect.com
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The mouse IgE genomic locus and IgE reporter mice. (a) IgE exists in a membrane B cell receptor form, which associates with the alpha and beta
subunits of CD79, and a secreted form. Both forms contain four immunoglobulin constant domains (CH1 to CH4), but the membrane form contains
additional transmembrane (TM) and cytoplasmic (CYT) domains. The mouse IgE genomic locus consists of four exons encoding each of the heavy
chain constant domains (CH1 to CH4), an exon encoding the transmembrane domain of membrane IgE (M1), and an exon encoding the cytoplasmic
domain of membrane IgE (M2). There are two polyadenylation sites (A) associated with secreted IgE that are located between the CH4 and M1 exons,
and three polyadenylation sites associated with membrane IgE that are located downstream of the M2 exon. The three polyadenylation sites
downstream of the M2 exon contain suboptimal sequences that result in lower levels of membrane IgE transcript. (b) M1 prime GFP knockin mice
contain an insertion of an IRES-GFP bicistronic reporter gene with an exogenous polyadenylation sequence downstream of the M2 exon of the
membrane IgE gene, as well as an insertion of the M1 prime domain of human membrane IgE (a 52 amino acid N-terminal extension of the
transmembrane M1 domain of human membrane IgE) into its comparable location in the mouse IgE locus [12]. Concerns have been raised that the
insertion of the human M1 prime and/or the exogenous polyadenylation sequences may have affected membrane IgE expression or function in M1
prime GFP mice [13]. Since there were no differences in primary or memory IgE and IgG1 responses between wildtype and M1 prime GFP mice upon
infection with N. brasiliensis or immunization with TNP-OVA, and there were also no differences in membrane IgE expression on in vitro-derived IgE-
positive B cells in IgE switch cultures, it was concluded that these modifications did not significantly affect IgE or IgG1 responses or membrane IgE
expression and function [12,15]. Verigem mice contain an in-frame insertion of a viral 2A peptide sequence and Venus yellow fluorescent protein at the
end of the M2 exon of the membrane IgE gene [18]. During protein translation, the 2A peptide causes a skip that ultimately yields two separate
proteins: membrane IgE with an additional C-terminal 17 amino acid 2A peptide extension and the Venus protein. In addition, Verigem mice contain an
insertion of a furin cleavage site at the 30 end of the CH4 exon, which is a remnant of the original targeting vector. The modifications at the IgE locus in
Verigem mice do not appear to significantly affect IgE responses or membrane IgE expression and function, since no significant differences in
phenotype, differentiation, or behavior of IgE germinal center B cells or plasma cells were observed in Verigem mice compared to wildtype mice.
CeGFP mice contain an insertion of an IRES-GFP bicistronic reporter gene downstream of the end of the M2 exon of the membrane IgE gene [17].differentiate into short-lived IgE plasma cells [18].
Studies of M1 prime GFP knockin mice [14,15] and
CeGFP mice [17] also demonstrated a transient IgE
germinal center response and the generation of primarily
short-lived IgE plasma cells, although the studies of
CeGFP mice suggested that IgE germinal center B cells
are predisposed to undergo apoptosis as opposed to
differentiate into plasma cells. Thus, the persistence of
IgE production in mice is limited by a transient germinal
center response and a short lifespan of IgE-producing
plasma cells.
Although most IgE plasma cells produced in mice are
short-lived cells that reside in the lymph nodes and
spleen, a small number of IgE plasma cells were found
in the bone marrow in Verigem mice, M1 prime GFP
knockin mice, and CeGFP mice [14,17,18]. These
cells are likely to be long-lived IgE plasma cells thatwww.sciencedirect.com contribute to low levels of sustained IgE antibody pro-
duction, consistent with other studies that have identified
long-lived IgE plasma cells in the bone marrow of wild-
type mice [22,23].
Very little is known about the memory B cells that give
rise to IgE memory responses. Studies of M1 prime GFP
knockin mice have identified a small population of IgE-
positive memory B cells and a small subpopulation of
IgG1-positive memory B cells that give rise to IgE
responses when transferred to B cell-deficient recipient
mice and rechallenged with antigen [14,16]. In these
studies, it was calculated that the IgE memory B cells
contributed to the majority of the IgE memory response.
By contrast, studies of mice with monoclonal T cells and
B cells [17,19] have identified IgG1 memory B cells as
the major source of IgE memory responses. In these
studies, however, IgE and IgG1 memory B cells wereCurrent Opinion in Immunology 2014, 31:8–15
10 Allergy and hypersensitivitynot purified and compared directly, and therefore it is
possible that the contributions of IgE memory B cells
were not fully accounted for due to their low frequency in
the mixed cell populations that were examined. Overall,
the understanding of the sources of IgE memory is
limited and remains controversial.
Targeting IgE production
Taken together, the studies in mice have delineated a
pathway of IgE production and memory that results in
primarily transient, short-lived IgE antibody responses
and limited IgE memory (Figure 2). This model for IgE
production and memory suggests that a significant pro-
portion of IgE antibody is generated from ongoing naı¨ve
and/or memory B cell activation and differentiation into
IgE-producing plasma cells and implies that IgE antibody
levels could be significantly reduced by inhibiting new
IgE production, such as by targeting the cytokines IL-4Figure 2
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Current Opinion in Immunology 2014, 31:8–15 and IL-13 to inhibit IgE class switch recombination or by
targeting IgE-switched B cells directly. In addition, this
model also implies that a significant proportion of long-
term IgE memory could be eliminated by targeting IgE-
switched memory B cells, although the IgG1 memory B
cells that contribute to IgE memory would not be affected
by this approach.
Studies in mice and monkeys have shown that
deficiency or neutralization of IL-4, IL-13, or the re-
ceptor IL-4Ra that is shared by both IL-4 and IL-13,
inhibits IgE production [24–27], but only a few studies
have assessed the effect of neutralization of IL-4/IL-13
during an ongoing or established IgE response [28]. A
study in a cynomolgus monkey model of IgE responses
to Ascaris suum antigen showed that treatment with
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although no significant changes in total IgE levels were
observed [25].
Multiple groups have directly targeted IgE-switched B
cells using antibodies that bind either specifically to the
membrane IgE BCR or to both membrane and secreted
IgE [12,29–37], with several groups demonstrating in
vivo activity of these antibodies [12,33–37]. Early stu-
dies showed that polyclonal and monoclonal anti-mouse
IgE antibodies could inhibit primary and memory IgE
responses, but did not prevent the development of IgE
memory [35,36]. More recently, an antibody specific for
mouse membrane IgE, which could trigger apoptosis of
IgE B cells in vitro, inhibited IgE production when
administered to mice preventively, but not when
administered during an ongoing IgE response [34].
However, memory IgE responses in mice treated with
this antibody during initial immunizations were signifi-
cantly reduced long after treatment was stopped,
suggesting that the antibody may have prevented the
development of IgE memory B cells [34].
Antibodies targeting the M1 prime domain of human
membrane IgE, which could trigger apoptosis and
mediate antibody-dependent cell-mediated cytotox-
icity of IgE B cells in vitro, inhibited both primary
and memory IgE responses in M1 prime GFP knockin
mice [12]. When administered during an ongoing IgE
response in a mouse model of allergic asthma, these
antibodies reduced antigen-specific IgE levels to levels
comparable to those in naı¨ve mice and far below the
levels present at the initiation of treatment [12]. These
antibodies also inhibited human IgE production in
immunodeficient mice that were reconstituted with
human immune cells [12,29]. In a different study,
anti-IgE antibodies that bound both serum and mem-
brane IgE were engineered for increased binding to the
inhibitory IgG receptor FcgRIIb [33]. By binding both
membrane IgE and FcgRIIb simultaneously  on IgE-
switched B cells, these antibodies inhibit membrane
IgE signaling. When administered either preventively
or during an ongoing IgE response in mice expressing a
human FcgRIIb receptor or in immunodeficient mice
reconstituted with human immune cells, these anti-
bodies reduced IgE levels by greater than 90%. This
in vivo activity required the co-engagement of mem-
brane IgE with FcgRIIb.
Interestingly, two groups have reported high expression
of membrane IgE on IgE plasma cells in mice [17,18],
and therefore therapies that target membrane IgE-
expressing cells may directly target not only IgE-switched
B cells, but also IgE plasma cells. However, none of the
studies discussed above determined the direct effect of
the membrane IgE-targeted therapeutics on IgE plasma
cells.www.sciencedirect.com Effects of antibodies targeting IL-13, IL-4Ra,
and the M1 prime domain of human
membrane IgE on IgE production in clinical
studies
It has been difficult to study IgE production in humans
due to the low abundance of IgE-switched cells and
technical limitations in identifying them. The limited
available data on human IgE responses is largely consist-
ent with what has been observed in mice. For instance,
significant seasonal increases and decreases in allergen-
specific and total IgE levels in allergic individuals, con-
sisting of as much as two-fold changes observed over the
course of several months, is reminiscent of the transient
IgE responses observed in mice [38–40]. However,
reports of long-term helminth-specific IgE [41] or the
transfer of allergen-specific IgE to non-atopic recipients
of bone marrow transplants [42,43] indicate that, in con-
trast to mice, there may be a significant contribution of
long-lived IgE plasma cells to IgE production in humans.
In addition, studies of patients with asthma and allergic
rhinitis have described significant local IgE production in
nasal and bronchial mucosal tissues [44], which has not
been reported in mice.
Recently, therapeutic agents that target IgE production
have been assessed in small Phase I and Phase II clinical
studies (Table 1). These agents include therapeutics that
target IL-4 (altrakincept), IL-13 (lebrikizumab,
GSK67586, IMA-638, IMA-026, tralokinumab), IL-4Ra
(dupilumab, AMG-317, pitrakinra), and membrane IgE
(quilizumab). In reviewing the clinical data, it should be
noted that differences in the effects of these therapeutic
agents on IgE production may result from differences in
the potencies of the various therapeutics against their
respective targets, differences in therapeutic exposure
due to different routes of administration and/or dosing
frequencies, as well as differences in the characteristics of
the patient cohorts in each clinical study.
The effect of neutralizing IL-13 and/or IL-4 on IgE
production in humans has been assessed in a number
of different clinical studies. Treatment with lebrikizu-
mab, an anti-IL-13 monoclonal antibody, reduced total
serum IgE levels by approximately 20% in patients with
asthma [45,46,47]. In these studies, proximal biomarkers
of IL-13 blockade (e.g. FeNO and CCL17) revealed near-
maximal inhibition of IL-13 activity following a single
dose, whereas serum IgE levels declined more slowly
during the 3–6 month treatment period. Since the half-
life of serum IgE in humans is very short (approximately
1–2 days), these results are consistent with a slow decline
in serum IgE upon the turnover of short-lived IgE plasma
cells downstream of the inhibition of IL-13-induced IgE
class switching. These studies also suggest that at least
20% of total serum IgE in these patients was generated
from ongoing IgE B cell responses (which can be driven
by both IL-4 and IL-13). By contrast, the anti-IL-13Current Opinion in Immunology 2014, 31:8–15
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Table 1
Summary of clinical studies.
Target Therapeutic Molecule Asthma patient
population
Treatment
duration
IgE reduction relative
to pre-treatment
(mean %)
Reference
IL-4 Altrakincept
(nebulized)
Soluble IL-4Ra
protein
Moderate 12 weeks No effect [50]
IL-13 Lebrikizumab Anti-IL-13 antibody Mild; no ICS 13 weeks 24% [47]
Lebrikizumab Anti-IL-13 antibody Mild-moderate; no ICS 12 weeks 12% [46]
Lebrikizumab Anti-IL-13 antibody Moderate-severe,
uncontrolled
24 weeks 22% [45]
GSK67586 Anti-IL-13 antibody Severe, uncontrolled 12 weeks No effect [48]
IMA-638,
IMA-026
Anti-IL-13 antibodies Mild; no ICS 1 month No effect [49]
Tralokinumab Anti-IL-13 antibody Moderate-severe,
uncontrolled
13 weeks No data available [55]
IL-13 and IL-4 AMG-317 Anti-IL-4Ra antibody Moderate-severe 12 weeks 49% (mean)
7% (median)
[52]
Dupilumab Anti-IL-4Ra antibody Moderate-severe,
uncontrolled; ICS taper
12 weeks 37% [53]
Pitrakinra
(nebulized)
IL-4 variant protein Atopic asthma 1 month No effect [51]
Membrane IgE
(M1 prime
domain)
Quilizumab Anti-M1 prime
antibody
Mild; no ICS 12 weeks 19% [54]monoclonal antibodies IMA-638, IMA-026, and
GSK67586 failed to demonstrate effects on serum IgE
in clinical studies [48,49], but differences in antibody
potencies, antibody exposure, and/or clinical study design
may have contributed to the lack of effect as compared to
lebrikizumab.
The contribution of IL-4 to IgE production in patients with
asthma is less clear. Blockade of IL-4 using a soluble
recombinant IL-4Ra protein (altrakincept) did not result
in reductions in serum IgE, although this therapeutic was
delivered via nebulization and therefore would have had
only local effects in the lung, with very little systemic
activity [50]. Similarly, blockade of both IL-4 and IL-13
using a nebulized variant IL-4 protein that binds to IL-4Ra
but does not activate signaling (pitrakinra) did not have any
effect on serum IgE [51]. By contrast, blockade of both IL-
4 and IL-13 using monoclonal antibodies against IL-4Ra
(AMG-317 and dupilumab) administered subcutaneously
reduced total serum IgE levels [52,53]. Due to differ-
ences in patient populations and study designs, it is not
possible to accurately assess whether blockade of IL-4
activity in addition to IL-13 activity by these anti-IL-
4Ra agents had an incremental effect on reducing serum
IgE compared to IL-13 blockade alone.
Quilizumab is an afucosylated monoclonal antibody
against the M1 prime domain of human membrane IgE
[29], which enables the direct therapeutic targeting of IgE-
switched cells. The effect of quilizumab on IgE production
has been assessed in three independent small phase I and
II studies [54]. In patients with mild asthma, quilizumab
treatment completely inhibited new allergen-specific IgECurrent Opinion in Immunology 2014, 31:8–15 production induced by whole lung allergen challenge
[54]. In addition, quilizumab treatment resulted in a
gradual reduction in total serum IgE levels in healthy
volunteers, patients with allergic rhinitis, and patients with
mild asthma [54]. The kinetics and extent of serum IgE
reduction were similar following one or several dose admin-
istrations of quilizumab and were also similar to the
reductions in total serum IgE observed upon blockade
of IL-13 or IL-4Ra, consistent with this proportion of total
serum IgE arising from short-lived plasma cells generated
from ongoing IgE B cell responses. The residual total
serum IgE levels that were not affected by quilizumab
treatment may have been produced by long-lived IgE
plasma cells that were not targeted by quilizumab. Inter-
estingly, the reductions in total serum IgE were sustained
at least six months after the last dose of quilizumab,
suggesting that treatment with quilizumab may have abro-
gated some memory IgE responses that were contributing
to ongoing IgE production, which were not regenerated
upon the cessation of quilizumab therapy.
Conclusions
Studies of IgE production using genetically modified IgE
reporter mice have revealed that most IgE in mice is
produced by short-lived IgE plasma cells arising from
ongoing IgE B cell responses. IgE responses in mice are
transient, due to a limited persistence of IgE germinal
center responses and the short life span of most IgE-
producing plasma cells. IgE memory responses remain
poorly understood, and the sources of IgE memory are
controversial, although both IgE and IgG1 memory B cells
have been implicated. Further studies of IgE production in
mice are needed to better define the mechanisms that limitwww.sciencedirect.com
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switched cells to differentiate into short-lived plasma cells,
as well as the sources of IgE memory.
Results of clinical studies of agents targeting IL-4 and/or
IL-13, as well as membrane IgE, indicate that a significant
proportion of IgE in humans arises from short-lived IgE
plasma cells and ongoing IgE B cell responses, similar to
that observed in mice. However, the human clinical
studies also suggest that a major proportion of IgE in
humans, larger than that observed in mice, may arise from
long-lived IgE plasma cells. It should be noted that
differences in mouse models of IgE production compared
to IgE production in humans may account for the differ-
ences in the effects of therapeutics in mice versus
humans. For instance, mouse models of IgE responses
are acute models with defined time points of immuniz-
ation and therapeutic intervention. By contrast, patients
treated with therapeutics have longstanding IgE
responses arising from multiple previous allergic chal-
lenges, which may result in different proportions of short-
lived versus long-lived plasma cells and differences in the
extent to which therapeutic agents can reduce existing
IgE levels. In addition, most mouse models employ one
specific antigen/allergen for immunization and exposure,
whereas allergic individuals typically have many different
IgE specificities, some or all of which may contribute to
disease pathogenesis.
Although the results of the clinical studies indicate that
IL-13 plays an important role in IgE class switch recom-
bination to generate IgE in humans, the contribution of
IL-4 to IgE production remains to be clarified. Further
studies are also needed to better understand the fre-
quency and drivers of IgE class switching in humans,
as well as the contribution of short-lived versus long-lived
plasma cells to the total serum IgE pool in allergic
patients, especially those with very high levels of IgE.
In addition, studies are needed to define whether there
are differential contributions of IgE generated from short-
lived versus long-lived plasma cells, or from IgE produced
in different anatomical locations, to disease pathogenesis
in humans. An increased understanding of IgE production
in health and disease may lead to new therapies for the
treatment of allergic diseases.
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